Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- North Brunswick, New Jersey
- Most recent report
- 6-K, filed Aug 19, 2026
- Incorporated
- Delaware
- Filings on record
- 100 filings
- On EDGAR
- CIK 1944552
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Emerging growth company
Financials 8 of 24
- 6-K Report a foreign issuer made public elsewhere Aug 19, 2026
- 6-K Report a foreign issuer made public elsewhere Aug 14, 2026
- 6-K Report a foreign issuer made public elsewhere Aug 3, 2026
- 6-K Report a foreign issuer made public elsewhere Jul 17, 2026
- 6-K Report a foreign issuer made public elsewhere Apr 16, 2026
- 20-F Annual report, foreign issuer Apr 10, 2026
- 6-K Report a foreign issuer made public elsewhere Apr 1, 2026
- 6-K Report a foreign issuer made public elsewhere Feb 12, 2026
Prospectuses and Registrations 5
Ownership 8 of 27
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- 3 Insider reported their initial holding Aug 4, 2026
- 3 Insider reported their initial holding Jul 15, 2026
- 4 Insider reported a trade Jun 10, 2026
- 3 Insider reported their initial holding Jun 1, 2026
- 3 Insider reported their initial holding May 28, 2026
- 4 Insider reported a trade May 21, 2026
Other 8 of 44
- 424B7 Jul 20, 2026
- EFFECT Notice that a registration became effective Apr 28, 2026
- CORRESP Reply to SEC staff Apr 24, 2026
- F-3/A Amended filing Apr 24, 2026
- F-3/A Amended filing Apr 23, 2026
- UPLOAD Comment letter from SEC staff Mar 10, 2026
- 20-F/A Annual report, foreign issuer, amended May 12, 2025
- UPLOAD Comment letter from SEC staff Feb 27, 2025
Everything here comes from Adlai Nortye Ltd.'s own filings on SEC EDGAR. The filing list is rechecked every hour.